Prostate-Specific Membrane Antigen Expression Is a Potential Prognostic Marker in Endometrial Adenocarcinoma
Uloženo v:
| Název: | Prostate-Specific Membrane Antigen Expression Is a Potential Prognostic Marker in Endometrial Adenocarcinoma |
|---|---|
| Autoři: | Mhawech-Fauceglia, P., Smiraglia, D. J., Bshara, W., Andrews, C., Schwaller, J., South, S., Higgs, D., Lele, S., Herrmann, F., Odunsi, K. |
| Zdroj: | Cancer Epidemiology, Biomarkers & Prevention, Vol. 17, No 3 (2008) pp. 571-577 |
| Informace o vydavateli: | American Association for Cancer Research (AACR), 2008. |
| Rok vydání: | 2008 |
| Témata: | Adult, Glutamate Carboxypeptidase II, 0301 basic medicine, Down-Regulation, Immunoenzyme Techniques, 618.97, 03 medical and health sciences, 0302 clinical medicine, Cell Line, Tumor, Biomarkers, Tumor, Humans, Aged, Proportional Hazards Models, Aged, 80 and over, Antigens, Surface/*metabolism, Analysis of Variance, Reverse Transcriptase Polymerase Chain Reaction, Middle Aged, Prognosis, Endometrial Neoplasms, 3. Good health, Glutamate Carboxypeptidase II/*metabolism, ddc:618.97, Antigens, Surface, Female, Endometrial Neoplasms/*metabolism, Tumor Markers, Biological/metabolism |
| Popis: | The aim of this study was to determine the role of prostate-specific membrane antigen (PSMA) as a prognostic marker in endometrial adenocarcinoma (EAC) and to explore whether its down-regulation could be due to epigenetic mechanism. First, we examined the expression and the prognostic value of PSMA by semiquantitative reverse transcription-PCR and immunohistochemistry in EAC tissue samples. Second, to explore the role of CpG methylation in down-regulation PSMA in EAC, we evaluated PSMA CpG island methylation using methylation-specific PCR in cells lines and in a subset of patients' samples. Furthermore, association of the status of tumor methylation to the clinical and histologic variables was also evaluated. Higher PSMA mRNA levels were associated with stage I (P = 0.046) and PSMA protein intensity by immunohistochemistry (P = 0.032). In multivariate analysis, loss of PSMA expression was associated with a worse disease-free survival (P = 0.02). PSMA was methylated in prostate cell lines (DU145 and PC3) and endometrial cell lines. In addition, PSMA was methylated in 5 of 18 samples (all 5 had low PSMA mRNA value). There was a significant association between PSMA methylation and loss of protein expression by immunohistochemistry and PSMA-RNA level with P value of 0.036 and 0.011, respectively. In addition, there was an association between PSMA methylation and tumor size (P = 0.025). In summary, (a) PSMA is underexpressed in advanced stage EAC, (b) loss of PSMA expression can be considered as a prognostic marker in patients with EAC, and (c) loss of PSMA expression in a subset of EAC cases could be due to epigenetic silencing. (Cancer Epidemiol Biomarkers Prev 2008;17(3):571–7) |
| Druh dokumentu: | Article |
| Popis souboru: | application/pdf |
| Jazyk: | English |
| ISSN: | 1538-7755 1055-9965 |
| DOI: | 10.1158/1055-9965.epi-07-0511 |
| Přístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/18349274 https://edoc.unibas.ch/29983/ https://www.ncbi.nlm.nih.gov/pubmed/18349274 https://cebp.aacrjournals.org/content/17/3/571.full.pdf+html http://cebp.aacrjournals.org/content/17/3/571.full https://cebp.aacrjournals.org/content/cebp/17/3/571.full.pdf https://archive-ouverte.unige.ch/unige:19071 https://archive-ouverte.unige.ch/unige:19071 |
| Přístupové číslo: | edsair.doi.dedup.....b44ae2e9184c87891280031fd2b46d23 |
| Databáze: | OpenAIRE |
Nájsť tento článok vo Web of Science | Abstrakt: | The aim of this study was to determine the role of prostate-specific membrane antigen (PSMA) as a prognostic marker in endometrial adenocarcinoma (EAC) and to explore whether its down-regulation could be due to epigenetic mechanism. First, we examined the expression and the prognostic value of PSMA by semiquantitative reverse transcription-PCR and immunohistochemistry in EAC tissue samples. Second, to explore the role of CpG methylation in down-regulation PSMA in EAC, we evaluated PSMA CpG island methylation using methylation-specific PCR in cells lines and in a subset of patients' samples. Furthermore, association of the status of tumor methylation to the clinical and histologic variables was also evaluated. Higher PSMA mRNA levels were associated with stage I (P = 0.046) and PSMA protein intensity by immunohistochemistry (P = 0.032). In multivariate analysis, loss of PSMA expression was associated with a worse disease-free survival (P = 0.02). PSMA was methylated in prostate cell lines (DU145 and PC3) and endometrial cell lines. In addition, PSMA was methylated in 5 of 18 samples (all 5 had low PSMA mRNA value). There was a significant association between PSMA methylation and loss of protein expression by immunohistochemistry and PSMA-RNA level with P value of 0.036 and 0.011, respectively. In addition, there was an association between PSMA methylation and tumor size (P = 0.025). In summary, (a) PSMA is underexpressed in advanced stage EAC, (b) loss of PSMA expression can be considered as a prognostic marker in patients with EAC, and (c) loss of PSMA expression in a subset of EAC cases could be due to epigenetic silencing. (Cancer Epidemiol Biomarkers Prev 2008;17(3):571–7) |
|---|---|
| ISSN: | 15387755 10559965 |
| DOI: | 10.1158/1055-9965.epi-07-0511 |